Stocktoria
Voyager Therapeutics, Inc. VYGR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2015-11-11
Voyager Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $40.4M | $80.0M | $250.0M | $40.9M | $37.4M |
| R&D expense | $134.7M | $127.4M | $92.2M | $60.8M | $73.8M |
| Operating income | -$131.8M | -$83.3M | $122.0M | -$50.8M | -$73.6M |
| Income tax | $144,000 | $665,000 | $1.4M | $16,000 | — |
| Net income | -$119.7M | -$65.0M | $132.3M | -$46.4M | -$71.2M |
| EPS (diluted) | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 |
| Operating cash flow | -$132.5M | -$15.3M | $77.9M | -$12.5M | -$53.5M |
| Free cash flow | -$135.1M | -$18.8M | $74.7M | -$15.0M | -$55.1M |
| Cash & equivalents | $65.3M | $71.4M | $68.8M | $99.0M | $117.4M |
| Total assets | $252.3M | $393.1M | $351.3M | $159.4M | $193.9M |
| Total liabilities | $56.2M | $93.3M | $115.0M | $100.3M | $98.8M |
| Shareholders' equity | $196.1M | $299.8M | $236.3M | $59.0M | $95.1M |
Source: SEC EDGAR filings · CIK 0001640266 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.